These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 18223473

  • 41. Limited sampling strategies for the estimation of sirolimus daily exposure in kidney transplant recipients on a calcineurin inhibitor-free regimen.
    Cattaneo D, Cortinovis M, Baldelli S, Gotti E, Remuzzi G, Perico N.
    J Clin Pharmacol; 2009 Jul; 49(7):773-81. PubMed ID: 19491334
    [Abstract] [Full Text] [Related]

  • 42. Development of a predictive limited sampling strategy for estimation of mycophenolic acid area under the concentration time curve in patients receiving concomitant sirolimus or cyclosporine.
    Figurski MJ, Nawrocki A, Pescovitz MD, Bouw R, Shaw LM.
    Ther Drug Monit; 2008 Aug; 30(4):445-55. PubMed ID: 18641543
    [Abstract] [Full Text] [Related]

  • 43. Calcineurin Inhibitor Determination in Whole Blood With the RXL Dimension Analyzer: A Useful Tool for Immunosuppressive Drug Monitoring.
    Ventura E, Bonardet A, Pageaux GP, Mourad G, Cristol JP.
    Transplant Proc; 2009 Mar; 41(2):707-9. PubMed ID: 19328963
    [Abstract] [Full Text] [Related]

  • 44. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
    Skalicka B, Kubanek M, Malek I, Vymetalova Y, Hoskova L, Podzimkova M, Kautzner J.
    J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021
    [Abstract] [Full Text] [Related]

  • 45. Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients.
    Leather H, Boyette RM, Tian L, Wingard JR.
    Biol Blood Marrow Transplant; 2006 Mar; 12(3):325-34. PubMed ID: 16503502
    [Abstract] [Full Text] [Related]

  • 46. South American Heart Transplantation Registry of patients receiving everolimus in their immunosuppressive regimens.
    Bortman GV, Ceruti B, Ahualli L, Colque R, Amuchástegui M, Sgrosso JL, Muñoz J, Vulcano N, Burgos C, Diez F, Rodriguez MC, Perrone SV.
    Transplant Proc; 2010 Mar; 42(1):324-7. PubMed ID: 20172342
    [Abstract] [Full Text] [Related]

  • 47. Increase in renal vascular resistance after intake of cyclosporin A and tacrolimus and reversal by nitroglycerin spray: a study in patients with stable renal allograft function.
    Weingart C, Leingärtner T, Bergler T, Krüger B, Böger C, Mack M, Banas B, Krämer BK.
    Int J Clin Pharmacol Ther; 2006 Sep; 44(9):422-7. PubMed ID: 16995330
    [Abstract] [Full Text] [Related]

  • 48. Impaired erythropoietin production in liver transplant recipients: the role of calcineurin inhibitors.
    Bardet V, Junior AP, Coste J, Lecoq-Lafon C, Chouzenoux S, Bernard D, Soubrane O, Lacombe C, Calmus Y, Conti F.
    Liver Transpl; 2006 Nov; 12(11):1649-54. PubMed ID: 17058250
    [Abstract] [Full Text] [Related]

  • 49. Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients.
    David-Neto E, Agena F, Ramos F, Triboni AHK, Romano P, de Almeida Rezende Ebner P, Coelho V, Galante NZ, Lemos FBC.
    Transplantation; 2017 Sep; 101(9):2133-2138. PubMed ID: 27798513
    [Abstract] [Full Text] [Related]

  • 50. Tacrolimus in diabetic kidney transplant recipients: pharmacokinetics and application of a limited sampling strategy.
    Mendonza AE, Zahir H, Gohh RY, Akhlaghi F.
    Ther Drug Monit; 2007 Aug; 29(4):391-8. PubMed ID: 17667791
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Fast LC-MS/MS analysis of tacrolimus, sirolimus, everolimus and cyclosporin A in dried blood spots and the influence of the hematocrit and immunosuppressant concentration on recovery.
    Koster RA, Alffenaar JW, Greijdanus B, Uges DR.
    Talanta; 2013 Oct 15; 115():47-54. PubMed ID: 24054560
    [Abstract] [Full Text] [Related]

  • 53. [Therapeutic monitoring of immunosuppressive drugs: interest of calcineurin activity assessment in liver transplantation].
    Blanchet B.
    Ann Pharm Fr; 2008 Mar 15; 66(2):96-101. PubMed ID: 18570908
    [Abstract] [Full Text] [Related]

  • 54. Sirolimus pharmacokinetic differences between children and adults.
    Venkataramanan R, Sindhi R.
    Pediatr Transplant; 2006 Dec 15; 10(8):872-4. PubMed ID: 17096752
    [No Abstract] [Full Text] [Related]

  • 55. Flexible limited sampling model for monitoring tacrolimus in stable patients having undergone liver transplantation with samples 4 to 6 hours after dosing is superior to trough concentration.
    Langers P, Press RR, den Hartigh J, Cremers SC, Baranski AG, Lamers CB, Hommes DW, van Hoek B.
    Ther Drug Monit; 2008 Aug 15; 30(4):456-61. PubMed ID: 18641539
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Everolimus with reduced-dose cyclosporine in de novo renal transplant recipients: Philippine experience.
    Li JT, Danguilan RA, Cabanayan-Casasola CB, Talusan-Tomacruz Y, Ona ET.
    Transplant Proc; 2008 Sep 15; 40(7):2211-3. PubMed ID: 18790195
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.